Sysmex Europe
Menu

Please select your country. This will keep you up to date with your country-specific information.

OSNA in lung cancer

  • Precise lymph node (LN) analysis providing accurate staging
  • Reliable diagnostic information supporting treatment decisions
  • Multi-cancer application allowing highly efficient analysis runs
  • CE-marked for breast, colon, gastric and lung cancer

Documents

All
  • All
  • Brochure
Documents

The best treatment decision relies on accurate staging

In non-small cell lung cancer (NSCLC), surgery remains the best chance of cure for early stage patients. However, up to 30% of those patients experience recurrences after surgery [1]. This is in part due to occult metastases in the lymph nodes that are missed by standard histology, which analyses only a small portion of the node [2]. This is a major concern since nodal status determines patient survival and guides intra- and post-operative treatment decisions. Furthermore, the clinical trend is moving toward de-escalation of surgical treatment with the aim to improve patient quality of life and to reduce comorbidities, such as poor pulmonary and cardiac function.

Unlike histopathological methods, OSNA (one-step nucleic acid amplification) enables a fast, molecular whole-node analysis. It provides nodal staging and prognosis accuracy as well as an improved basis for personalised fully-informed treatment decisions in the most common subtypes [3] of lung cancer. Thanks to a fast and accurate intra-operative staging, OSNA can enable pioneer thoracic surgeons and pathologists who have already implemented marginal or sentinel lymph node biopsy in lung cancer to reduce excision radicality (lung tissue and lymph nodes) in node-negative cases.

OSNA offers a molecular analysis by quantifying the expression of CK19 mRNA, reflecting the metastatic burden in the LN. Among various markers with high expression in lung cancer, CK19 reported the best performance to detect LN metastases [4]. OSNA has been compared to conventional histology and resulted in high concordance (96.2%) and sensitivity (100%)[5-6]. By detecting more LN metastases than histology, OSNA led to a higher pTNM stage in 22% of patients[7].

OSNA – superior diagnostic information

  • Confidence for the pathologists to not overlook metastases
  • Enables immediate and fully-informed decisions already during surgery
  • Offers an improved basis for personalised treatment decisions

Oncology

OSNA – Sentinel lymph
node analysis

References

References

[1] Franco et al. (2008): Detection of micrometastases in pN0 non-small cell lung cancer: an alternative method combining tissue microarray and immunohistochemistry. J Bras Pneumo.
[2] Rusch et al. (2011): Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: Report of the ACOSOG Z0040 trial. J Clin Oncol.
[3] Adenocarcinoma and Squamous cells carcinoma as described in the OSNA IFU (version 1909)
[4] Inoue et al. (2012): An accurate and rapid detection of lymph node metastasis in non-small cell lung cancer patients based on one-step nucleic acid amplification assay. Lung Cancer.
[5] Pérez et al. (2019): Detection of lymph node metastasis in lung cancer patients using a one-step nucleic acid amplification assay: a single-centre prospective study. J Transl Med.
[6] Hayama et al. (2014): One-step nucleic acid amplification for detection of lymph node metastasis in lung cancer. Ann Thorac Cardiovasc Surg.
[7] Vodicka et al. (2018): A more sensitive detection of micrometastases of NSCLC in lymph nodes using the one-step acid amplification (OSNA) method. J Surg Oncol.

OSNA Lung in clinical studies

OSNA Lung in clinical studies

Please see the OSNA Lung publication list

Contact

Sysmex Europe GmbH

+49 (40) 527 26 0
+49 (40) 527 26 100
oncology@sysmex-europe.com
Bornbarch 1
22848 Norderstedt
Germany

Create Pdf

Workflow of OSNA RD-210

Watch video
Enjoy our Media Centre
All
  • All
  • Documents
  • Podcast
  • Images
  • Videos
See our collection
Find your job